Maternal HIV antibody testing, with patient consent, is a routine component of prenatal care. An HIV test is recommended for all women who are pregnant, or planning a pregnancy regardless of their risk factors or the prevalence rates where they live. Proper diagnosis and treatment can improve the health of the mother and dramatically reduce the transmission of HIV from mother to infant.

**Implementation Steps**

At the first OB visit, discuss the following with the patient:

- An HIV antibody test is recommended as a routine part of prenatal care. It will be routinely offered to all patients for the following reasons:
  - HIV can be transmitted from the mother to the fetus or newborn during the pregnancy, the birth process or breast feeding.
  - Treatment is available that will significantly reduce the transmission rate.
  - A risk assessment will not identify all HIV-infected pregnant women.

- Before HIV testing, provide the following minimum information: (although a face-to-face counseling session is ideal, other methods can be used (e.g., brochure, pamphlet, or video) if they are culturally and linguistically appropriate. A possible source of materials is the American College of Obstetricians and Gynecologists at [http://www.acog.org/About-ACOG/News-Room/News-Releases/2014/New-Guidelines-Address-Screening-Prevention-of-HIV-in-Women](http://www.acog.org/About-ACOG/News-Room/News-Releases/2014/New-Guidelines-Address-Screening-Prevention-of-HIV-in-Women) and [http://www.acog.org/-/media/For-Patients/pfs005.pdf?dmc=1&ts=20141114T1511039539](http://www.acog.org/-/media/For-Patients/pfs005.pdf?dmc=1&ts=20141114T1511039539).
  - HIV is the virus that causes AIDS. HIV is spread through unprotected sexual contact and injection-drug use. Approximately 25% of HIV-infected pregnant women who are not treated during pregnancy can transmit HIV to their infants during pregnancy, during labor and delivery, or through breast-feeding.
  - A woman might be at risk for HIV infection and not know it, even if she has had only one sex partner.
  - Effective interventions (e.g., antiretroviral medication combinations) for HIV-infected pregnant women can protect their infants from acquiring HIV and can prolong the survival and improve the health of these mothers and their children.
  - For these reasons, HIV testing is recommended for all pregnant women.
  - Services are available to help women reduce their risk of acquiring HIV and to provide medical care and other assistance to those who are infected.
  - Women who decline testing will not be denied care for themselves or their infants.

- Obtain informed consent prior to testing; women should not be tested without their knowledge.

- Inform the patient that a positive HIV test will be reported by name to MDH, as are other reportable STD’s.
HIV Screening for Pregnant Women and Their Infants

Universal Opt-Out Screening (Minnesota is an Opt-Out state)

- All pregnant women in the United States should be screened for HIV infection.
- Screening should occur after a woman is notified that HIV screening is recommended for all pregnant patients and that she will receive an HIV test as part of the routine panel of prenatal tests unless she declines (opt-out screening).
- HIV testing must be voluntary and free from coercion. No woman should be tested without her knowledge.
- Pregnant women should receive oral or written information that includes an explanation of HIV infection, a description of interventions that can reduce HIV transmission from mother to infant, and the meanings of positive and negative test results and should be offered an opportunity to ask questions and to decline testing. One patient education fact sheet is: [http://www.acog.org/-/media/For-Patients/pfs005.pdf?dmc=1&ts=20141114T1511039539](http://www.acog.org/-/media/For-Patients/pfs005.pdf?dmc=1&ts=20141114T1511039539)
- No additional process or written documentation of informed consent beyond what is required for other routine prenatal tests should be required for HIV testing.
- If a patient declines an HIV test, this decision should be documented in the medical record.

Addressing Reasons for Declining Testing

- Providers should discuss and address reasons for declining an HIV test (e.g., lack of perceived risk; fear of the disease; and concerns regarding partner violence or potential stigma or discrimination).
- Women who decline an HIV test because they have had a previous negative test result should be informed of the importance of retesting during each pregnancy.
- Logistical reasons for not testing (e.g., scheduling) should be resolved.
- Certain women who initially decline an HIV test might accept at a later date, especially if their concerns are discussed. Certain women will continue to decline testing, and their decisions should be respected and documented in the medical record.

Timing of HIV Testing

- Health-care providers should test women for HIV as early as possible during each pregnancy. Women who decline the test early in prenatal care should be encouraged to be tested at a subsequent visit.
- A second HIV test during the third trimester, preferably <36 weeks of gestation, is cost-effective even in areas of low HIV prevalence and may be considered for all pregnant women. A second HIV test during the third trimester is recommended for women who meet one or more of the following criteria:
  - Women who receive health care in facilities in which prenatal screening identifies at least one HIV-infected pregnant woman per 1,000 women screened.
  - Women who are known to be at high risk for acquiring HIV (e.g., injection-drug users and their sex partners, women who exchange sex for money or drugs, women who are sex partners of HIV-infected persons, and women who have had a new or more than one sex partner during this pregnancy).
  - Women who have signs or symptoms consistent with acute HIV infection. When acute retroviral syndrome is a possibility, a plasma RNA test should be used in conjunction with an HIV antibody test to diagnose acute HIV infection.

Documentation

- Document in the medical record information discussed with patient about HIV and testing as well as whether the patient accepts or declines an HIV antibody test.
- Include the HIV antibody test in the prenatal lab panel.
If Patient Declines an HIV Test

- Continue to recommend an HIV test as a routine component of prenatal care at subsequent visits.
- Refusing to be tested must not have detrimental consequences to the quality of prenatal care.

Testing During Labor

- Any woman with undocumented HIV status at the time of labor should be screened with a rapid HIV test unless she declines the test.
- MN Perinatal HIV Nurse Coordinator is available to coordinate and support intrapartum and newborn care. This service is available free of charge to any provider or hospital in MN. (612) 387-2989 (cell) (http://www.health.state.mn.us/divs/idepc/diseases/hiv/testingguide.html#resources) Immediate initiation of appropriate antiretroviral prophylaxis should be recommended to women on the basis of a reactive rapid test result without waiting for the result of a confirmatory test.
ALGORITHM FOR HIV TESTING DURING PREGNANCY

At first OB visit provide information about HIV and discuss reason for test and confidential reporting to MDH if positive

Patient agrees to an HIV test

Patient declines an HIV test

Document in patient’s record

Continue to recommend an HIV test as routine at subsequent visits and document in patient’s record

Perform an HIV test, as part of lab panel

Negative Results
- PrEP Positive Partner*

Positive Results
- Inform patient of MDH Partner Services Program
  - http://www.health.state.mn.us/divs/idepc/dtopics/stds/partnerservices.html

  - Report case to MDH
    - 651-201-5414

* If positive partner, refer to information on PrEP

Inform patient at next scheduled appointment and reinforce prevention of HIV transmission

Retest in the third trimester, preferably before 36 weeks gestation, if woman is known to be at high risk for acquiring HIV

Introduce PrEP for future family planning

Continue prenatal care
Rapid Testing

Women admitted for labor and delivery with unknown or undocumented HIV status should be assessed promptly for HIV infection to allow for timely prophylactic treatment. The use of Rapid Testing (with confirmation by a second licensed test when available) is an option. There are currently five rapid HIV tests approved by the U.S. Food and Drug Administration (FDA) and commercially available in the U.S.:

<table>
<thead>
<tr>
<th>Test kit name</th>
<th>Manufacturer</th>
<th>Specimen type</th>
<th>CLIA Category</th>
<th>Equipment Required</th>
</tr>
</thead>
<tbody>
<tr>
<td>OraQuick ADVANCE Rapid HIV-1 Antibody Ora Quick Rapid HIV-1 Antibody Test</td>
<td>OraSure Technologies <a href="http://www.orasure.com">http://www.orasure.com</a></td>
<td>Whole Blood</td>
<td>Waived-Whole blood</td>
<td>Timer</td>
</tr>
<tr>
<td>Uni-Gold Recombigen HIV-1</td>
<td>Trinity Biotech <a href="http://www.trinitybiotech.com">www.trinitybiotech.com</a></td>
<td>Whole Blood</td>
<td>Waived-Whole blood</td>
<td>Timer</td>
</tr>
<tr>
<td>Clearview HIV 1/2Stat-Pack and COMPLETE 1/2Test Kits</td>
<td>Alere <a href="http://www.alere.com">www.alere.com</a></td>
<td>Serum or Plasma Whole Blood</td>
<td>Waived-Whole blood</td>
<td>Timer</td>
</tr>
<tr>
<td>INSTI HIV-1 Antibody Test</td>
<td>BioLytical Laboratories <a href="http://www.biolytical.com">www.biolytical.com</a></td>
<td>Whole blood Serum or Plasma</td>
<td>Waived</td>
<td>Timer</td>
</tr>
<tr>
<td>Alere Determine HIV-1/2AF/Ab Combo</td>
<td>Alere <a href="http://www.AlereHIV.com">www.AlereHIV.com</a></td>
<td>Serum or Plasma Whole Blood</td>
<td>CLIA-moderate complexity</td>
<td>Timer</td>
</tr>
</tbody>
</table>

Test Results:

For Negative Test Results, discuss the following:
- Window period, particularly if risk behaviors are present.
- Negative test result does not imply immunity to future infection.
- Reinforce ways to prevent transmission of HIV.
- Retest in the future, including the third trimester-before 36 weeks gestation, if evidence of risk (e.g. STD diagnosis, multiple partners).

For Positive Test Results, discuss the following:
- The meaning of an HIV positive test, HIV and AIDS.
- Medical care, including treatment for the mother’s health and to reduce the risk of transmission.
- Notify MDH of positive test result (http://www.health.state.mn.us/divs/idepc/dtopics/reportable/forms/hivform.html )
- Notification of partners and explore risk of any domestic violence. *
- Recommend testing of partners and children. *
- Consult or refer to an HIV specialist for treatment, and a Pediatric HIV Specialist for baby’s follow up care.

* MDH Partner Services Program contacts all newly diagnosed HIV positive individuals (http://www.health.state.mn.us/divs/idepc/dtopics/stds/partnerservices.html )

If test is being done in the presence of active labor, a positive Rapid test result warrants the initiation of IV Retrovir prophylaxis. A confirmatory test is still sent.
Resources

Information on Care Coordination for Pregnant HIV+ Women and Training and Education on Perinatal HIV:

Susan Dicker, RN, MS, MPH  
Perinatal HIV Nurse Coordinator  
Children’s Hospital and Clinics of MN  
347 North Smith Avenue, Suite 504  
St. Paul, Minnesota 55102  
(612) 387-2989 (cell)  
(651) 220-6444 (office)  
(651) 220-7233 (fax)  
Susan.Dicker@childrensmn.org

Tamara Harvanko R.N.  
High Risk OB Clinical Care Coordinator  
Hennepin County Medical Center  
701 Park Ave SL 120  
Minneapolis, MN 55415  
Direct: 612-873-6552  
Pager: 612-336-0327  
tamara.harvanko@hcmed.org

Information for Care of Newborns Perinatally Exposed to HIV:

Stacene Maroushek, MD  
Hennepin County Medical Center  
Department of Pediatrics,MC-867B  
701 Park Avenue South  
Minneapolis Minnesota 55415  
(612) 589-3100

Kiran Belani, MD  
Children’s Hospitals and Clinics  
347 North Smith Avenue, # 5080  
St. Paul, Minnesota 55102  
(651) 220-6444

Laura Hoyt, MD  
Children’s Hospitals and Clinics  
347 North Smith Avenue, # 5080  
St. Paul, Minnesota 55102  
(651) 220-6444

Information for HIV Care of Pregnant Women:

Laura Hoyt, MD  
Susan Kline, MD  
Tim Schacker, MD  
Fairview-University Medical Center  
Box 88 Mayo, 420 Delaware St. S.E.  
Minneapolis, Minnesota 55455  
(612) 625-4680

Frank Rhame, MD  
The Doctors, Allina Medical Clinic  
1300 Lagoon Avenue  
Minneapolis, Minnesota 55408

Keith Henry, MD  
Ron Schut, MD  
Kay Schwebke, MD  
Margaret Simpson, MD  
Virginia Lupo, MD (OB/GYN)  
Hennepin County Medical Center  
701 Park Avenue South  
Minneapolis, Minnesota 55415  
(612) 873-6963

mn-tel: HIV Consultation Network

HIV/AIDS clinical support & consultation services for healthcare providers  
Call MATEC at 612-626-3609 for more information  
http://mnmatec.umn.edu/

Information about Disease Reporting:

Adriana DiStaolo  
Sue Bedard-Johnson  
Minnesota Department of Health  
STD and HIV Section  
625 Robert Street North  
Minneapolis, MN 55107  
(651) 201-5414

Assistance with HIV Partner Notification:

MDH STD/MDH Partner Services Program  
http://www.health.state.mn.us/divs/idepc/dtopics/stds/partnerservices.html  
Call the Partner Services Program at 651-201-5414

HIV Perinatal Clinical Resources:

UCSF Clinical Consultation Center  
http://nccc.ucsf.edu/clinician-consultation/perinatal-hiv-aids/

UCSF Clinical Consultation Center  
“Frequently Asked Questions about HIV Testing”  